A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

NCT04418297 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped The termination criteria of the protocol was met during dose escalation

Conditions

Cardiomyopathy, Hypertrophic Obstructive

Interventions

DRUG: CT-G20
DRUG: Placebo

Sponsor

Celltrion